RDD is focused on developing targeted therapeutics and delivery systems for treating diseases of the anorectal region and lower gastrointestinal tract.
In order to treat diseases in this challenging area, drugs require special formulation and delivery/application techniques to address wide variations in anatomy and physiology.
The anorectal region has unique physiological challenges including high temperature and humidity, frequent passage of stools that scrape the surface and varying absorptive capacity of the various membranes.
Because of these physiological challenges and the high cost of developing new drugs, RDD Pharma has made a strategic decision to concentrate R&D on repurposing existing approved molecules that can be brought quickly and inexpensively to market.
RDD aims to provide targeted pharmacological treatments for diseases of the anorectal region such as anal fissures, fecal incontinence and pruritus ani. Additionally, a molecule targeting radiation proctitis is in preclinical development.
Please see our Strategy page for a detailed explanation of how New Therapeutic Entities (NTEs) can repurpose existing, approved molecules to provide low cost/fast-track alternatives to the risky, cost and time-intensive pharmaceutical approval timeline.
Our primary focus is on fast-track development and commercialization of innovative therapeutics for anorectal diseases and gastrointestinal disorders.